Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Artificial Tear

ApprovedSmall molecule

BBRIM Biotechnology Inc.

Artificial Tear is one of 82 small molecule programs targeting Myopia. It is currently in Approved.

4

Indications

12

Total Trials

3

Active Trials

81

Competitors

Pipeline

Status by Indication[3][1]

Indication

MyopiaActive, not recruiting

HordeolumActive, not recruiting

Eye DiseaseActive, not recruiting

Dry Eye SyndromeActive, not recruiting

MyopiaPreclinical

Active, not recruiting

HordeolumPhase 3

Active, not recruiting

Eye DiseaseApproved

Active, not recruiting

Dry Eye SyndromeApproved

Active, not recruiting

Competition

Competitive Landscape

200 competitors in Eye Disease

#DrugCompanyPhaseTrials

Neoral

Alphagan

Chantix

Bayer Aspirin

Zovirax

BBp Consulting, Inc

Artificial Tear

BBRIM Biotechnology Inc.

CF101

CCan-Fite BioPharma

Refresh Plus

REFRESH LIQUIGEL

Refresh Optive

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Not yet recruiting

Eye Disease

NCT07078955

Clinical

Trials by Indication[1]

Eye Disease2 trials

A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease

Not yet recruiting·BBRIM Biotechnology Inc.·Phase 2·NCT07078955·99 enrolled

Evaluating the Efficacy of Topical Insulin for the Restoration of Ocular Surface Interface in Dry Eye Disease.

Recruiting·KKhyber Teaching Hospital·Phase 4·NCT06939959·126 enrolled

Dry Eye Syndrome1 trial

Tear Film Markers in Dry Eye Syndrome

Withdrawn·VVishal Jhanji·Phase 4·NCT04515329

Myopia1 trial

Topical Application of Low-concentration (0.01%) Atropine on the Human Eye With Fast and Slow Myopia Progression Rate

Completed·TThe Hong Kong Polytechnic University·N/A·NCT03374306·71 enrolled

Hordeolum1 trial

Comparison of Combination Antibiotics Eyedrop to Artificial Tear in Hordeolum After Incision and Curettage

Unknown status·—·Phase 3·NCT00534391·120 enrolled

Efficacy and Safety1 trial

Clinical Trial to Determine the Efficacy and Safety of Insulin Eye Drops in Dry Eye in Patients with Topical Hypotensors

Recruiting·BBarbara Burgos Blasco·Phase 4·NCT06017362·100 enrolled

6 more indications

Treatment1 trial

Effects of Dry Eye Treatments on the Ocular Surface

Completed·—·Phase 4·NCT01797822·20 enrolled

Adenovirus1 trial

Ganciclovir 0,15% Ophthalmic Gel in the Treatment of Adenovirus Keratoconjuntivitis

Completed·FFederal University of São Paulo·N/A·NCT01349452·33 enrolled

Dry Eye1 trial

Acupoint Therapy Device for Dry Eye

Completed·SShanghai 10th People's Hospital·N/A·NCT06720428·120 enrolled

Vitamin D31 trial

Impact of Vitamin D3 Supplementation in Non-Sjogren Dry Eye Patients With Low Serum Vitamin D Level

Completed·UUniversity of Faisalabad·Phase 3·NCT05425914·108 enrolled

ART1 trial

Influence of Artificial Tears on Keratometry and Biometry Measurements With Different Devices

Completed·—·N/A·NCT06358456·145 enrolled

Intravitreal Injections1 trial

Comparison of the Efficacy of Nepafenac 0.1% and Nepafenac 0.3 % on Pain Associated With Intravitreal Injections

Completed·UUniversity Hospital of Patras·N/A·NCT03406689·99 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Artificial Tear. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Artificial Tear compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Artificial Tear. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BRIM Biotechnology Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: BBRIM Biotechnology Inc.

Related News